Helicobacter Pylori And Abdominal Pain

Definition And Microbiology

Gram-negative, microaerophilic spiral bacterium (S-shaped rod).
Exclusively colonizes the human stomach, localizing deep within the mucosal layer.
Produces abundant urease, catalase, and oxidase.
Classified as a Group I carcinogen; causes chronic active gastritis, peptic ulcer disease (PUD), gastric adenocarcinoma, and mucosa-associated lymphoid tissue (MALT) lymphoma.

Factor	Mechanism Of Action
Urease Enzyme	Converts gastric urea to ammonia; neutralizes the highly acidic local environment (pH 2.0 to 5.5-7.5) to create a survival microenvironment.
Flagella And Chemotaxis	Provide corkscrew motility; allow migration through the mucus layer guided by pH gradients.
Adhesins (BabA, SabA)	Bind to Lewis b ABO blood group antigens and sialic acid on host gastric epithelium; mediate initial attachment and colonization.
CagA	Cytotoxin-associated gene A oncoprotein is injected via Type IV Secretion System; alters host cell cytoskeleton and induces massive IL-8 production, strongly associating with PUD risk.
VacA	Vacuolating cytotoxin embeds into host cell membranes, disrupts the epithelial barrier, and induces massive intracellular vacuoles leading to cell collapse and death.

Lack Of Causal Link: Meta-analyses of multiple pediatric trials show absolutely no evidence linking general recurrent abdominal pain to H. pylori infection in children.
Specific Pain Pattern: Epigastric pain is the only pain phenotype demonstrating a significant statistical association with H. pylori infection.
Underlying Organic Disease: Abdominal pain is definitively linked to H. pylori only when the gastritis has progressed to secondary structural damage, such as duodenal or gastric peptic ulceration.
Diagnostic Recommendations: Routine screening for H. pylori is strictly not recommended in children fulfilling Rome IV criteria for functional abdominal pain without alarm signs.
Justified Testing: Investigation is justified exclusively for suspected organic disease (PUD), refractory iron deficiency anemia, or chronic idiopathic thrombocytopenic purpura.

Gold Standard: Esophagogastroduodenoscopy (EGD) with mucosal biopsy.
- Visual Findings: The hallmark pediatric finding is marked antral nodularity, presenting with a gooseflesh or cobblestone appearance.
- Biopsy Protocol: Minimum of 6 samples required (two from the antrum and two from the corpus for histology; the remaining for culture and rapid urease testing).
- Histopathology: Giemsa or Warthin-Starry silver stain highlights organisms adhering to the epithelium; accompanied by severe neutrophilic and lymphocytic infiltrate.
Rapid Urease Test: Rapid bedside detection of ammonia production utilizing a biopsy gel medium.

Test Modality	Clinical Utility And Interpretation
Stool Antigen Test	Monoclonal ELISA is highly accurate (97% sensitivity and specificity); preferred for initial diagnosis and confirming post-treatment eradication.
13C-Urea Breath Test	Highly sensitive and specific in children >6 years; detects expired 13CO2 generated by bacterial urease.
Serology (IgG/IgA)	Unreliable with poor specificity; cannot distinguish active from past infection and is strictly not recommended for clinical use.

Target Goal: Achieve $\geq$ 90% eradication rate on the initial attempt.
Treatment Duration: 10 to 14 days.
Standard Triple Therapy: High-dose proton pump inhibitor (PPI) combined with amoxicillin and clarithromycin (or metronidazole, depending on local resistance patterns).

Indicated strictly for primary treatment failure or proven antimicrobial resistance.
Sequential Therapy: A 10-day regimen utilizing a PPI and amoxicillin for 5 days, immediately followed by a PPI, clarithromycin, and metronidazole/tinidazole for 5 days.
Bismuth-Based Quadruple Therapy: Consists of a PPI, bismuth salts, amoxicillin, and metronidazole; highly effective in dual-resistance settings.

Mandatory for all treated patients.
Perform non-invasive testing (stool antigen or urea breath test) strictly 4 to 8 weeks post-treatment completion.
Confirmation testing must occur at least 2 weeks after discontinuing PPI therapy to avoid false-negative results.